2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - New Orleans Theatre C
Treatment Considerations, Combination Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Diseases, Lymphoid Malignancies, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly
PAPER

76 Pola-R2 in unfit/frail older patients with newly diagnosed DLBCL: Complete cohort analysis shows high CR rate and durable 24-month PFS

Wei Wang, Hongmei Jing I, MD2, Wenrong Huang, Professor/Chief Physician3, Zhitao Ying4, Yujun DONG, MD,PhD5, Yan Zhang, MD6, Jian Li, MD7
1 Peking Union Medical College Hospital, Beijing, China
2 Peking University Third Hospital, Beijing, China
3 the Fifth Medical Center of Chinese PLA General Hospital, Beijing, China
4 Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
5 Peking University First Hospital, Beijing, China
6 Peking Union Medical College Hospital, Beijing, China
7 Peking Union Medical College Hospital, Beijing, China

Background: Diffuse large B cell lymphoma is prevalent in older patients, but treatment remains non-standardized for those unfit/frail by comprehensive geriatric assessment (CGA). R-miniCHOP, the current standard for this population, achieves CR rates of only 40%-60%, and long-term survival remains poor. To address this unmet need, we designed a prospective phase II study (NCT06176729) to evaluate frontline polatuzumab vedotin, rituximab, and lenalidomide (Pola-R2) in this population. Here, we report the analysis of this complete cohort.

Methods: We enrolled patients aged 70 or older who had untreated DLBCL and were classified as unfit or frail by CGA. Patients received up to eight 21-day cycles of polatuzumab vedotin, rituximab, and lenalidomide. The primary endpoint was end-of-treatment (EOT) complete response rate (CRR) by PET/CT. The sample size (n=30) was powered to detect a strict CRR improvement from 40% (historical R-miniCHOP) to 70%. Baseline ctDNA profiling was performed in all patients; serial Roche HyperCAP ctDNA monitoring and paired lymphocyte subset profiling were performed in available subsets.

Results: As of July 16, 2026, thirty patients completed planned accrual. Median age was 82.5 years (range, 73-95); 20 (66.7%) were aged >=80 years and 6 (20.0%) were frail. Twenty-seven patients (90.0%) were in Ann Arbor stage III-IV, and 18 (60.0%) had IPI scores of 4-5. Early responses were promising at cycle 4, with an ORR of 96.7%, including a 63.3% CRR. At the end of treatment, the strict CRR reached 86.7% (26/30), exceeding the predefined 70% target. With a median follow-up of 23.5 months, the estimated 24-month PFS and OS were 86.7% and 90.0%.

Baseline ctDNA profiling identified recurrent mutations in PIM1 (53.3%), MYD88 (43.3%), CD79B (30.0%) and TP53(16.7%). Exploratory analyses suggested a possible association between TP53-mutated features and inferior PFS, although the number was limited. Twelve patients had serial ctDNA monitoring, the median molecular burden declined sharply from 638.8 MMPM at baseline to 0.20 at first post-treatment assessment and 0 at last assessment; 8 (66.7%) achieved ctDNA clearance. PFS events occurred in 1 of 8 patients with ctDNA clearance versus 2 of 4 without clearance. In 19 patients with paired samples, we observed a significant expansion of CD8 effector-memory T cells (from 15.5% to 27.9%, P=0.020) and total CD8 T cells (from 28.9% to 40.2%, P=0.045), alongside a reduction in CD4+PD-1+ T cells (from 15.1% to 8.1%, P=0.023). The most common grade 3-4 adverse event was neutropenia/febrile neutropenia (40.0%); peripheral neuropathy was all in grade 1-2.

Conclusion: Frontline Pola-R2 met its prespecified primary endpoint. This regimen achieved high response rates and durable 24-month disease control, along with ctDNA clearance and possible immune remodeling, in this patient population. These findings support Pola-R2 as a promising frontline strategy for older DLBCL patients.

Wei Wang: No relevant conflicts of interest to declare.